Cellular Mechanisms of Interleukin-12-mediated Neuroblastoma Regression
Overview
Pediatrics
Authors
Affiliations
Background/purpose: Interleukin-12 (IL-12) is a proinflammatory cytokine with potent antitumor effects. Previous studies from the authors laboratory showed regression of established neuroblastoma in mice vaccinated with IL-12 transduced dendritic cells (DC). Although regression was associated with intense T cell infiltration, the precise role of T cells is unknown. The purpose of this work is to study the cellular mechanisms in IL-12-mediated tumor regression.
Methods: Three groups of mice (n = 12) received subcutaneous inoculation with 1 x 10(6) murine neuroblastoma cells (TBJ). Anti-CD4 (T helper), anti-CD8 (T cytotoxic), or antiasialo-GM1 (natural killer) antibodies were injected intravenously at 3-day intervals to deplete various immune effector cell populations. Mice in each depletion group and the control (nondepleted) group were injected intratumorally on day 7 with 1 x 10(6) DC IL-12-transduced DC. Tumors were harvested for morphometry and immunohistochemistry at 21 days.
Results: CD4 depletion had no effect on tumor growth in either control or IL-12-vaccinated animals. In contrast, CD8-depleted animals treated with IL-12-transduced DC underwent initial regression followed by progressive tumor growth (P <.01). These tumors were smaller in size at the same time-point. However, NK cell depletion (antiasialo GM1) completely abrogated the antitumor effects of IL-12-transduced DC, leading to progressive tumor growth from the outset. There was no difference between the control and treated animals in this group.
Conclusions: Contrary to our hypothesis that IL-12 DC primarily function to stimulate a T cell-mediated response, these data suggest that NK cells are essential for the initial antitumor response of animals treated with IL-12-transduced DC. CD8+ T cells appear to be necessary effector cells for complete rejection of tumor and possibly memory. NK cells are responsible for the early immune response. Furthermore, CD4+ (T helper) cells did not play any role in IL-12-induced regression. These results imply that for DC to generate an effective antitumor response against neuroblastoma both acquired and innate effector cells are required.
Gillory L, Megison M, Stewart J, Mroczek-Musulman E, Nabers H, Waters A PLoS One. 2013; 8(10):e77753.
PMID: 24130898 PMC: 3795073. DOI: 10.1371/journal.pone.0077753.
Immune therapies for neuroblastoma.
Navid F, Armstrong M, Barfield R Cancer Biol Ther. 2009; 8(10):874-82.
PMID: 19342881 PMC: 2712572. DOI: 10.4161/cbt.8.10.8358.
Salcedo R, Hixon J, Stauffer J, Jalah R, Brooks A, Khan T J Immunol. 2009; 182(7):4328-38.
PMID: 19299733 PMC: 2730673. DOI: 10.4049/jimmunol.0800471.
IL-12 immunotherapy of murine leukaemia: comparison of systemic versus gene modified cell therapy.
Labbe A, Nelles M, Walia J, Jia L, Furlonger C, Nonaka T J Cell Mol Med. 2008; 13(8B):1962-1976.
PMID: 18624776 PMC: 6512371. DOI: 10.1111/j.1582-4934.2008.00412.x.